BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 31955224)

  • 1. Multiple genetic factors affecting the pharmacokinetic and pharmacodynamic processes of tacrolimus in Chinese myasthenia gravis patients.
    Meng HY; Li X; Jin WL; Yan CK; Dong XH; Xu Q; Peng YY; Li ZB; Li Y; Luo ZH; Xu LQ; Yang H
    Eur J Clin Pharmacol; 2020 May; 76(5):659-671. PubMed ID: 31955224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis.
    Chen D; Hou S; Zhao M; Sun X; Zhang H; Yang L
    Eur J Neurol; 2018 Aug; 25(8):1049-e80. PubMed ID: 29611886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Analysis of Tacrolimus in Adult Chinese Patients with Myasthenia Gravis: A Prospective Study.
    Liu J; Guo YP; Jiao Z; Zhao CB; Wu H; Li ZR; Cai XJ; Xi JY
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):453-466. PubMed ID: 32170643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP3A5*3 polymorphism and age affect tacrolimus blood trough concentration in myasthenia gravis patients.
    Fan Z; Zheng D; Wen X; Shen F; Lei L; Su S; Zhang S; Liu Q; Zhang X; Lu Y; Di L; Shen XM; Da Y
    J Neuroimmunol; 2021 Jun; 355():577571. PubMed ID: 33866281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.
    Hesselink DA; Bouamar R; Elens L; van Schaik RH; van Gelder T
    Clin Pharmacokinet; 2014 Feb; 53(2):123-39. PubMed ID: 24249597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trans-eQTLs of the CYP3A4 and CYP3A5 associated with tacrolimus trough blood concentration in Chinese renal transplant patients.
    Lu H; Jiang H; Yang S; Li C; Li C; Shao R; Zhang P; Wang D; Liu Z; Qi H; Cai Y; Xu W; Bao X; Wang H; Li L
    Biomed Pharmacother; 2022 Jan; 145():112407. PubMed ID: 34781138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between interleukin-18 promoter variants and tacrolimus pharmacokinetics in Chinese renal transplant patients.
    Xing J; Zhang X; Fan J; Shen B; Men T; Wang J
    Eur J Clin Pharmacol; 2015 Feb; 71(2):191-8. PubMed ID: 25487141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple microRNAs regulate tacrolimus metabolism through CYP3A5.
    Gu XQ; Tang D; Wan P; Qin T; Yang TH; Wu J; Ji H; Liu JC; Xue F; Tang YJ; Xia Q
    Pharmacol Res; 2021 Feb; 164():105382. PubMed ID: 33348024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
    Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
    Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
    Bruckmueller H; Werk AN; Renders L; Feldkamp T; Tepel M; Borst C; Caliebe A; Kunzendorf U; Cascorbi I
    Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and side effects of low-dose tacrolimus for the treatment of Myasthenia Gravis.
    Tao X; Wang W; Jing F; Wang Z; Chen Y; Wei D; Huang X
    Neurol Sci; 2017 Feb; 38(2):325-330. PubMed ID: 27873026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing.
    García-Roca P; Medeiros M; Reyes H; Rodríguez-Espino BA; Alberú J; Ortiz L; Vásquez-Perdomo M; Elizondo G; Morales-Buenrostro LE; Mancilla Urrea E; Castañeda-Hernández G
    Arch Med Res; 2012 May; 43(4):283-7. PubMed ID: 22704849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Rong G; Jing L; Deng-Qing L; Hong-Shan Z; Shai-Hong Z; Xin-Min N
    Transplant Proc; 2010 Nov; 42(9):3455-8. PubMed ID: 21094796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.